In terms of regulation 5(4) of the Control of Concentrations Regulations, 2002 published in Legal Notice 294 of 2002, the Director General of the Office for Competition notifies for general information that a notification of a concentration between Gland Pharma International Pte. Ltd (Telangana, India) and Phixen SAS (Fontenay-sous-Bois, France) was filed on Wednesday, 21 December 2022.
The nature of the concentration is an acquisition of Phixen SAS by Gland Pharma International Pte. Ltd.
Gland Pharma International Pte. Ltd is wholly and directly owned by Gland Pharma Limited, which is a contract development and manufacturing organisation that provides drug development and manufacturing services on behalf of third parties. Phixen SAS is part of the Cenexi Group, which is active in the formulation, analytical and process development and stability testing, amongst others. It also develops and manufactures injectable needs, on behalf of pharmaceutical companies. In Malta the parties are present in the sector of drug development and manufacturing services on behalf of third parties.
The Director General of the Office for Competition invites interested third parties to submit their written objections on this notified concentration within seven days following publication of this notice at the following address: